We are live on ! Find out more
AMED

Amedisys

Delisted

AMED was delisted on the 14th of August, 2025.

288 hedge funds and large institutions have $2.85B invested in Amedisys in 2024 Q2 according to their latest regulatory filings, with 42 funds opening new positions, 93 increasing their positions, 104 reducing their positions, and 32 closing their positions.

New
Increased
Maintained
Reduced
Closed

31% more first-time investments, than exits

New positions opened: 42 | Existing positions closed: 32

18% more funds holding in top 10

Funds holding in top 10: 1113 (+2)

2% more funds holding

Funds holding: 283288 (+5)

0.07% more ownership

Funds ownership: 94.92%94.99% (+0.07%)

0% less capital invested

Capital invested by funds: $2.86B → $2.85B (-$5.8M)

11% less repeat investments, than reductions

Existing positions increased: 93 | Existing positions reduced: 104

82% less call options, than puts

Call options by funds: $17.1M | Put options by funds: $94.3M

Holders
288
Holders Change
+5
Holders Change %
+1.77%
% of All Funds
4.16%
Holding in Top 10
13
Holding in Top 10 Change
+2
Holding in Top 10 Change %
+18.18%
% of All Funds
0.19%
New
42
Increased
93
Reduced
104
Closed
32
Calls
$17.1M
Puts
$94.3M
Net Calls
-$77.2M
Net Calls Change
-$8.21M
Name Holding Trade Value Shares
Change
Change in
Stake
GC
151
Guggenheim Capital
Illinois
$697K +$1.02K +11 +0.1%
A
152
AlphaQuest
New York
$674K +$356K +3,842 +110%
NMIMC
153
Northwestern Mutual Investment Management Company
Wisconsin
$669K +$464 +5 +0.1%
COPPSERS
154
Commonwealth of Pennsylvania Public School Employees Retirement System
Pennsylvania
$664K +$1.3K +14 +0.2%
HF
155
HRT Financial
New York
$656K -$644K -6,943 -49%
Nomura Holdings
156
Nomura Holdings
Japan
$653K -$3.27M -35,212 -83%
ETC
157
Exchange Traded Concepts
Oklahoma
$648K +$30.9K +333 +5%
Royal Bank of Canada
158
Royal Bank of Canada
Ontario, Canada
$645K -$1.73M -18,656 -73%
AIP
159
Ameritas Investment Partners
Nebraska
$637K -$35.1K -378 -5%
OPERF
160
Oregon Public Employees Retirement Fund
Oregon
$621K -$121K -1,300 -16%
Victory Capital Management
161
Victory Capital Management
Texas
$620K -$2.32K -25 -0.4%
VI
162
Versor Investments
New York
$617K +$119K +1,279 +24%
AQR Capital Management
163
AQR Capital Management
Connecticut
$611K -$94.1K -1,014 -13%
MML Investors Services
164
MML Investors Services
Massachusetts
$607K -$141K -1,522 -19%
NMERB
165
New Mexico Educational Retirement Board
New Mexico
$606K
Fidelity Investments
166
Fidelity Investments
Massachusetts
$596K +$112K +1,209 +23%
PCP
167
Pacific Capital Partners
$593K
BPC
168
Banque Pictet & Cie
Switzerland
$587K
Handelsbanken Fonder
169
Handelsbanken Fonder
Sweden
$574K
ST
170
Sabal Trust
Florida
$551K
Zurich Cantonal Bank
171
Zurich Cantonal Bank
Switzerland
$540K -$81.7K -881 -13%
Susquehanna International Group
172
Susquehanna International Group
Pennsylvania
$523K +$529K +5,701 New
VA
173
Vident Advisory
Georgia
$499K -$276K -2,975 -35%
VPIM
174
Vanguard Personalized Indexing Management
California
$498K +$57.4K +619 +13%
TI
175
Trexquant Investment
Connecticut
$481K -$903K -9,730 -65%

AMED Hedge Fund Activity: Q2 2024 in Review

288 of the 6,924 institutional investors tracked by Wall St. Rank reported a position in Amedisys (AMED) for Q2 2024, worth a combined $2.85B — down 0.2% from $2.86B a quarter earlier.

Buyers outnumbered sellers: 42 funds opened new AMED positions and 32 closed out — a net gain of 10 holders — while 93 added to existing stakes and 104 trimmed.

The largest buyer was Goldman Sachs, adding an estimated $96.9M. The largest seller was Millennium Management, cutting an estimated $32.3M.

  • 288 institutional investors held Amedisys (AMED) as of Q2 2024, up from 283 in Q1 2024.
  • Funds reported $2.85B of Amedisys stock for Q2 2024, down 0.2% quarter-over-quarter.
  • 42 funds opened new Amedisys positions in Q2 2024 and 32 closed out, a net change of +10 holders.
  • The largest Amedisys buyer in Q2 2024 was Goldman Sachs, an estimated $96.9M added.
  • The largest Amedisys seller in Q2 2024 was Millennium Management, an estimated $32.3M sold.

Based on aggregated 13F filings for Q2 2024.